MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412651 | Name: CGP-4832

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CGP-4832 is a semisynthetic derivative of rifamycin S, designed to enhance antibacterial activity, particularly against Gram-negative bacteria. It exhibits MIC values up to 400 times lower than rifampicin for certain strains of Escherichia coli and Salmonella. Some Klebsiella and Enterobacter strains also show high sensitivity. CGP-4832 inhibits DNA-dependent RNA polymerase, similar to rifampicin. CGP-4832 represents a significant improvement over rifampicin for treating Gram-negative infections, primarily due to its enhanced cellular uptake rather than differences in target inhibition.

Chemical Structure

CGP-4832
CGP-4832
CAS#113303-81-4

Theoretical Analysis

MedKoo Cat#: 412651

Name: CGP-4832

CAS#: 113303-81-4

Chemical Formula: C49H65N3O15

Exact Mass: 935.4416

Molecular Weight: 936.07

Elemental Analysis: C, 62.87; H, 7.00; N, 4.49; O, 25.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CGP 4832; CGP4832; CGP-4832
IUPAC/Chemical Name
Rifamycin, 25-((((1-methyl-3-piperidinyl)methyl)oxy)carbonyl)-3-(4-morpholinyl)-
InChi Key
FRCBXOTYSDSELT-DUULCSDKSA-N
InChi Code
InChI=1S/C49H65N3O15/c1-25-12-10-13-26(2)48(61)50-38-39(52-17-20-63-21-18-52)44(59)35-36(43(38)58)42(57)30(6)46-37(35)47(60)49(7,67-46)65-19-15-32(62-9)27(3)45(29(5)41(56)28(4)40(25)55)66-34(54)22-33(53)64-24-31-14-11-16-51(8)23-31/h10,12-13,15,19,25,27-29,31-32,40-41,45,55-57H,11,14,16-18,20-24H2,1-9H3,(H,50,61)/b12-10+,19-15+,26-13-/t25-,27+,28+,29+,31?,32-,40-,41+,45+,49-/m0/s1
SMILES Code
CO[C@H]1/C=C/O[C@]2(Oc3c(C2=O)c4c(C(C(NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(CC(OCC5CCCN(C5)C)=O)=O)C)O)C)O)C)=O)=C(C4=O)N6CCOCC6)=O)c(O)c3C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 936.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wehrli W, Zimmermann W, Kump W, Tosch W, Vischer W, Zak O. CGP 4832, a new semisynthetic rifamycin derivative highly active against some gram-negative bacteria. J Antibiot (Tokyo). 1987 Dec;40(12):1733-9. doi: 10.7164/antibiotics.40.1733. PMID: 2448280. 2: Ferguson AD, Ködding J, Walker G, Bös C, Coulton JW, Diederichs K, Braun V, Welte W. Active transport of an antibiotic rifamycin derivative by the outer- membrane protein FhuA. Structure. 2001 Aug;9(8):707-16. doi: 10.1016/s0969-2126(01)00631-1. PMID: 11587645. 3: Pugsley AP, Zimmerman W, Wehrli W. Highly efficient uptake of a rifamycin derivative via the FhuA-TonB-dependent uptake route in Escherichia coli. J Gen Microbiol. 1987 Dec;133(12):3505-11. doi: 10.1099/00221287-133-12-3505. PMID: 3332686. 4: Braun V. Active transport of siderophore-mimicking antibacterials across the outer membrane. Drug Resist Updat. 1999 Dec;2(6):363-369. doi: 10.1054/drup.1999.0107. PMID: 11498352. 5: Braun M, Killmann H, Braun V. The beta-barrel domain of FhuADelta5-160 is sufficient for TonB-dependent FhuA activities of Escherichia coli. Mol Microbiol. 1999 Sep;33(5):1037-49. doi: 10.1046/j.1365-2958.1999.01546.x. PMID: 10476037. 6: Killmann H, Braun M, Herrmann C, Braun V. FhuA barrel-cork hybrids are active transporters and receptors. J Bacteriol. 2001 Jun;183(11):3476-87. doi: 10.1128/JB.183.11.3476-3487.2001. PMID: 11344156; PMCID: PMC99646. 7: Khursigara CM, De Crescenzo G, Pawelek PD, Coulton JW. Enhanced binding of TonB to a ligand-loaded outer membrane receptor: role of the oligomeric state of TonB in formation of a functional FhuA.TonB complex. J Biol Chem. 2004 Feb 27;279(9):7405-12. doi: 10.1074/jbc.M311784200. Epub 2003 Dec 10. PMID: 14668326. 8: Killmann H, Herrmann C, Torun A, Jung G, Braun V. TonB of Escherichia coli activates FhuA through interaction with the beta-barrel. Microbiology (Reading). 2002 Nov;148(Pt 11):3497-3509. doi: 10.1099/00221287-148-11-3497. PMID: 12427941. 9: Endriss F, Braun M, Killmann H, Braun V. Mutant analysis of the Escherichia coli FhuA protein reveals sites of FhuA activity. J Bacteriol. 2003 Aug;185(16):4683-92. doi: 10.1128/jb.185.16.4683-4692.2003. PMID: 12896986; PMCID: PMC166461. 10: Braun M, Endriss F, Killmann H, Braun V. In vivo reconstitution of the FhuA transport protein of Escherichia coli K-12. J Bacteriol. 2003 Sep;185(18):5508-18. doi: 10.1128/jb.185.18.5508-5518.2003. PMID: 12949103; PMCID: PMC193757.

View History

CGP-54626 HCl

CGP-54626 HCl

Featured